American Journal of Clinical Nutrition, Vol 68, 42-51, Copyright © 1998 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Energy expenditure, body composition, and glucose metabolism in lean and obese rhesus monkeys treated with ephedrine and caffeine

JJ Ramsey, RJ Colman, AG Swick and JW Kemnitz
Wisconsin Regional Primate Research Center, University of Wisconsin, Madison 53715-1299, USA.

The administration of ephedrine and caffeine (E+C) has been proposed to promote weight loss by increasing energy expenditure and decreasing food intake. We tested this hypothesis in six lean (4-9% body fat) and six mildly to moderately obese (13-44% body fat) monkeys studied during a 7-wk control period, an 8-wk drug treatment period, and a 7-wk placebo period. During the drug treatment period, the monkeys were given ephedrine (6 mg) and caffeine (50 mg) orally three times per day. At the end of each period, a glucose tolerance test was performed, energy expenditure was measured, and body composition was determined. Treatment with E+C resulted in a decrease in body weight in the obese animals (P = 0.06). This loss in weight was primarily the result of a 19% reduction in body fat. Drug treatment also resulted in a decrease in body fat in the lean group (P = 0.05). Food intake was reduced by E+C only in the obese group (P < 0.05). Nighttime energy expenditure was increased by 21% (P < 0.03) in the obese group and 24% (P < 0.01) in the lean group with E+C treatment. Twenty-four-hour energy expenditure was higher in both groups during drug treatment. E+C did not produce systematic changes in glucoregulatory variables, whereas plasma leptin concentrations decreased in both groups with drug treatment. Overall, these results show that E+C treatment can promote weight loss through an increase in energy expenditure, or in some individuals, a combination of an increase in energy expenditure and a decrease in food intake.

This article has been cited by other articles:

				G. Natarajan, M. Lulic-Botica, and J.V. Aranda Pharmacology Review: Clinical Pharmacology of Caffeine in the Newborn NeoReviews, May 1, 2007; 8(5): e214 - e221. [Abstract] [Full Text] [PDF]

				K. Diepvens, K. R. Westerterp, and M. S. Westerterp-Plantenga Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R77 - R85. [Abstract] [Full Text] [PDF]

				E. Salazar-Martinez, W. C. Willett, A. Ascherio, J. E. Manson, M. F. Leitzmann, M. J. Stampfer, and F. B. Hu Coffee Consumption and Risk for Type 2 Diabetes Mellitus Ann Intern Med, January 6, 2004; 140(1): 1 - 8. [Abstract] [Full Text] [PDF]

				J. Bauer, K. Maier, O. Linderkamp, and R. Hentschel Effect of Caffeine on Oxygen Consumption and Metabolic Rate in Very Low Birth Weight Infants With Idiopathic Apnea Pediatrics, April 1, 2001; 107(4): 660 - 663. [Abstract] [Full Text] [PDF]

				S. N. Steen and E. Coleman Invited Review: Selected Ergogenic Aids Used by Athletes Nutr Clin Pract, December 1, 1999; 14(6): 287 - 295. [PDF]